Author/Authors :
Zafari ، Tahmine Department of Pediatric Cardiology - Islamic Azad University, Mashhad Medical Sciences Branch , Ajilian ، Narges Department of Pediatric Cardiology - Islamic Azad University, Mashhad Medical Sciences Branch , Mansouri ، Atena Department of Immunology - Innovated Medical Research Center - Islamic Azad University, Mashhad Branch , Sadr-Nabavi ، Ariane Department of Medical Genetics - Medical Genetics Research Center, Basic Medical Sciences Institute, Iranian Academic Center for Education, Culture and Research, (ACECR), Faculty of Medicine - Mashhad University of Medical Sciences , Esmaeili ، Alireza Department of Immunology - Immunology Research Center, Faculty of Medicine - Mashhad University of Medical Sciences , Jafarzadeh Esfehani ، Reza Department of Medical Genetics - Medical Genetics Research Center, Basic Medical Sciences Institute, Iranian Academic Center for Education, Culture and Research, (ACECR),Faculty of Medicine - Mashhad University of Medical Sciences , Abtahi ، Saeed Department of Pediatric Cardiology - Islamic Azad University, Mashhad Medical Sciences Branch
Abstract :
Background and Aims: Warfarin is an anticoagulant agent used for many years in treating various clinical conditions such as thromboembolisms in cardiovascular disease. Some patients require different doses of warfarin to reach the therapeutic international normalized ratio ratio. These patients have specific demographic characteristics. Genetic polymorphisms in specific genes have been reported to be an essential factor in response to warfarin. The present study investigated the effect of these polymorphisms of genes on warfarin dose necessities in pediatric of VCORC1 gene in patients. Material and Methods: Ninety-five patients with cardiovascular disease, who were receiving warfarin for at least three months, enrolled in the present cross-sectional study. Their genomic DNA was extracted from their peripheral blood, and the VKORC1 (rs9923231) polymorphism was evaluated by polymerase chain reaction and sequencing. Results: Among the study population, 48 patients (50.5%) had TC genotype and, 21 (22.1%) and 9 (9.5%) patients have TT and CC genotype, respectively. There was no significant relation between Warfarin dose and VCORC1 genotype in our population (p 0.05). Conclusions: The VKORC1 polymorphism (rs9923231) did not significantly affect the warfarin required for cardiovascular disease patients. Further studies evaluating other genes such as CYP2C9 polymorphisms in our population are warranted.
Keywords :
Cardiovascular disease , Genotype , Polymorphism , VKORC1 , Warfarin
